Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
<p>Abstract</p> <p>Background</p> <p>Alendronate (ALN) is the most common form of bisphosphonates used for the treatment of osteoporosis. Osteoprotegerin (OPG) has also been shown to reduce osteoporotic changes in both humans and experimental animals after systemic admi...
Main Authors: | Chan Kai-Ming, Tang Pei-Fu, Huang Peng, Wang Yan, Li Gang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-07-01
|
Series: | Journal of Orthopaedic Surgery and Research |
Subjects: | |
Online Access: | http://www.josr-online.com/content/6/1/34 |
Similar Items
-
Study of the incidence of osteoporosis in patients with Sjögren’s syndrome (pSS) and investigation of activation of the RANKL / RANK and osteoprotegerin (OPG) system
by: Charalampos Skarlis, et al.
Published: (2018-01-01) -
Heamatococcus pluvialis ameliorates bone loss in experimentally-induced osteoporosis in rats via the regulation of OPG/RANKL pathway
by: Farouk K. El-Baz, et al.
Published: (2019-08-01) -
Circular RNA atlas in osteoclast differentiation with and without alendronate treatment
by: Jianbiao Lin, et al.
Published: (2020-07-01) -
Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
by: Anne-Priscille Trouvin, et al.
Published: (2010-11-01) -
On the Role of Osteoprotegerin/RANK/RANKL System in the Interaction between Prostate Cancer and Bone
by: Penno, Hendrik
Published: (2011)